Friday, March 29, 2024
HomeLatest Pharma-NewsThe U.S. Food and Drug Administration granted accelerated approval for the ...

The U.S. Food and Drug Administration granted accelerated approval for the first targeted treatment, Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy

December 12, 2019: The U.S. Food and Drug Administration granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) for the patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

It is estimated that approximately 8 per cent of patients with DMD have this mutation. This is the new medical treatments for serious neurological disorders for the treatments for rare diseases.

- Advertisement -

DMD is a rare genetic disorder that is characterized by progressive muscle deterioration and weakness. It is caused by the absence of dystrophin, a protein that helps keep muscle cells intact.

Patients  with DMD progressively lose the ability to perform activities separately and often require a wheelchair by their early teens.

Vyondys 53 approved under the accelerated approval pathway that provides for the approval of drugs, treat serious or life-threatening diseases and generally offer a meaningful advantage over existing treatments. https://fda.einnews.com/pr_news/504734147/fda-grants-accelerated-approval-to-first-targeted-treatment-for-rare-duchenne-muscular-dystrophy-mutation

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular